News articles about Viking Therapeutics (NASDAQ:VKTX) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Viking Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.7020935229415 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several analysts recently weighed in on VKTX shares. ValuEngine upgraded Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. Maxim Group restated a “buy” rating and set a $5.00 target price on shares of Viking Therapeutics in a research note on Monday, September 11th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a research note on Friday, November 10th. Finally, Roth Capital started coverage on Viking Therapeutics in a research note on Tuesday, November 21st. They set a “buy” rating and a $5.00 target price for the company.
Shares of Viking Therapeutics (NASDAQ VKTX) opened at $4.04 on Monday. Viking Therapeutics has a 52 week low of $0.88 and a 52 week high of $4.33. The firm has a market capitalization of $140.24, a P/E ratio of -4.81 and a beta of 1.87.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.